1. Introduction {#sec1}
===============

Roux-en-Y gastric bypass (RYGB) results in substantial weight loss, averaging 30--40 kg (about 60% excess weight) \[[@B1]\] which can be sustained over 10--15 years \[[@B2]\]. RYGB also results in improvement of multiple comorbidities associated with obesity. About 75% of patients with type 2 diabetes who undergo RYGB are able to discontinue all diabetes-related medications and maintain normoglycemia \[[@B3]--[@B6]\]. Dyslipidemia improves or resolves in 70%--95% of surgically treated patients and hypertension in 87%--95% \[[@B5]\]. In addition, studies suggest that mortality may be decreased by as much as 40% \[[@B2], [@B7]\].

Long-term complications of RYGB remain incompletely understood. Known complications of the operation include anemia, vitamin and mineral deficiencies, peripheral neuropathy, short term surgical complications such as thromboembolism and small bowel obstruction, as well as dumping syndrome, anatomic complications such as herniation, ulceration or strictures, and multiple others \[[@B8]\]. Additionally, rarely patients may develop hyperinsulinemic hypoglycemia with neuroglycopenia that typically presents 2--5 years postoperatively \[[@B9]--[@B11]\]. The pathophysiology of postgastric bypass hyperinsulinemic hypoglycemia is not well understood. Hypoglycemia usually occurs two to three hours after meals \[[@B12]\]. Patients exhibit exaggerated incretin and insulin responses after food intake \[[@B13]--[@B15]\]. Alterations in other gut hormones, including peptide YY, ghrelin, and leptin, have also been implicated in glycemic patterns following RYGB \[[@B14], [@B16]--[@B19]\]. Pancreatic histology from the subset of severely affected patients requiring partial pancreatectomy has been consistent with nesidioblastosis in some studies, with *β*-cells demonstrating increased nuclear diameter, and increases in both large and small islets, some of irregular shape and many clustering near ducts \[[@B9], [@B10]\]. However, it remains uncertain whether there is true islet hyperplasia or increased *β*-cell mass in this syndrome, as control samples matched for obesity and major weight loss are not readily available \[[@B12], [@B20], [@B21]\].

The frequency of severe hypoglycemia following RYGB and potentially related complications requiring hospitalization, such as confusion, syncope, seizures, and/or accidental death, is conservatively estimated from Swedish national data to be about 0.2%. Although these data underestimate the risk of more mild hypoglycemia not requiring hospital evaluation, the relative risk of these severe complications is two- to sevenfold higher after bypass than in nonoperated persons \[[@B22]\]. Furthermore, glucose variability may be high following gastric bypass \[[@B15], [@B23]\].

In this study, we used continuous glucose monitoring (CGM) technology and mixed meal tolerance testing (MMTT) to evaluate patients who presented with clinically significant neuroglycopenia following RYGB in whom medical management had been initiated, as compared to patients who have no symptoms of hypoglycemia following gastric bypass. We hypothesized that CGM would be a useful clinical tool in this population and that glycemic variability would be better evaluated under real-life conditions at home than by a MMTT in clinical research testing conditions.

2. Materials and Methods {#sec2}
========================

The Internal Review Board of Joslin Diabetes Center approved this study. All subjects provided written informed consent. Subjects in the symptomatic group were referred for management of postgastric bypass neuroglycopenia, defined as documented hypoglycemia associated with altered mental status or level of consciousness, with or without seizure, requiring assistance of others. Because of the severity of their condition, all of the symptomatic patients had already been counseled regarding medical nutritional therapy, with emphasis on controlled portions of low glycemic index carbohydrates. In addition, at the time of study, 8 of 10 subjects in the symptomatic group were on *α*-glucosidase inhibitor therapy to reduce or delay dietary carbohydrate absorption to decrease the frequency of debilitating hypoglycemic episodes. One patient was on octreotide and one on diazoxide. This group is therefore referred to as the treated symptomatic group (TX-SX). Only one patient in this group had diabetes preoperatively; this individual was taking no diabetes medications and was without hyperglycemia at the time of study. Subjects did not have a diagnosis of hypoglycemia prior to surgery.

The control group comprised 6 women who had undergone laparoscopic RYGB who denied any current or previous symptoms characteristic of hypoglycemia, even upon careful questioning by study investigators (referred to as asymptomatic for hypoglycemia (ASX)). These subjects were recruited through advertisements in bariatric surgical clinics and local newspapers. None had known diabetes prior to RYGB. All subjects were weight stable, were similar in duration following RYGB to the TX-SX study group, and were otherwise in good health.

2.1. Mixed Meal Tolerance Testing {#sec2.1}
---------------------------------

Octreotide and diazoxide were held for 24 hours prior to MMTT, and *α*-glucosidase inhibitors were omitted on the morning of study. Given that subjects in the TX-SX group had severe hypoglycemic episodes, it was felt that a longer washout period would not be safe. Height and weight were measured using a wall-mounted stadiometer (Holtain Ltd., Crymych, UK) and electronic scale (model 0501; Acme Scale Co., San Leandro, CA). Subjects were studied following a 10--12 hour overnight fast. Fasting blood samples were obtained before a liquid mixed meal (Ensure, 9 g protein, 40 g carbohydrate, 6 g fat, 240 mL; Abbott Laboratories, Abbott Park, IL) with subsequent samples collected at 10, 20, 30, 60, and 120 minutes for measurement of glucose, insulin, and C-peptide.

During the MMTT, glucose was measured by glucose oxidation, fasting cholesterol and high-density lipoprotein (HDL) by cholesterol esterase assay, triglycerides via hydrolysis to glycerol, and hemoglobin A1c by HPLC (Tosoh 2.2; Tosoh Bioscience, San Francisco, CA). Insulin and C-peptide were measured in duplicate serum samples by radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX).

2.2. Continuous Glucose Monitoring {#sec2.2}
----------------------------------

Within one month after completion of the MMTT, study participants underwent placement of a continuous glucose monitor (Medtronic Minimed iPro, Medtronic, Northridge, CA). A study nurse inserted the CGM according to manufacturer directions and provided participants with instructions regarding CGM maintenance and capillary blood glucose monitoring every 6 hours for CGM calibration. Participants wore the CGM for at least 72, and up to 120, continuous hours; during that time, they kept a log documenting capillary blood glucose results as well as symptoms experienced at any time. CGM data were analyzed with Minimed iPro software version 2.1A.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Data are expressed as mean ± standard error unless otherwise indicated. Calculation of sensitivity and specificity for CGM and MMTT was performed according to the following formulas: sensitivity = number of true positives/(number of true positives + number of false negatives); specificity = number of true negatives/(number of true negatives + number of false positives). A true positive was defined as a numerical value of hypoglycemia (glucose \<70 mg/dL) during a test in a subject with the prior clinical occurrence of neuroglycopenia, as these patients (in the TX-SX group) had all had multiple episodes of well-documented hypoglycemia associated with altered mental status requiring assistance of others. A false positive was defined as a numerical value of hypoglycemia during a test in a subject with no history of symptomatic hypoglycemia (ASX) and no symptoms of hypoglycemia during the test (as self-reported on symptom log during CGM and as assessed by a study nurse during MMTT).

Two-tailed Student\'s *t*-test, or Mann-Whitney nonparametric test if data were not normally distributed, was used to compare the results between groups. Repeated measures ANOVA was used to compare variables at several time points after a mixed meal. Statistical analysis was performed using StatView (SAS Institute, Inc., Cary, NC). Significance was set at *P* \< .05.

3. Results and Discussion {#sec3}
=========================

3.1. Results {#sec3.1}
------------

Characteristics of the 16 subjects are summarized in [Table 1](#tab1){ref-type="table"}. Subjects in the treated symptomatic (TX-SX) group, who had symptomatic neuroglycopenia after gastric bypass, were similar to those who remained asymptomatic (ASX) with respect to age, preoperative and current body mass index (BMI), magnitude of weight loss and duration of time since RYGB; the TX-SX and ASX group were also similar with respect to hemoglobin A1c, lipid levels and blood pressure at time of study ([Table 1](#tab1){ref-type="table"}).

### 3.1.1. Mixed Meal Tolerance Test {#sec3.1.1}

Nine subjects in the TX-SX group and 5 subjects in the ASX group underwent MMTT; one subject in each group was unable to complete the test secondary to difficulties obtaining intravenous access. Fasting glucose was not different between the TX-SX and ASX group (73 ± 1 versus 75 ± 2 mg/dL; *P* = .4). Over the entire 2 hours, the blood glucose levels were likewise not different between the two groups. The area under the curve (AUC) for glucose (0--120 minutes) (3399 ± 695 versus 2285 ± 78 mg/dL/min; *P* = .5) and repeated measures ANOVA comparing the glucose levels over 2 hours were not significantly different (*P* = .2). However, at 120 minutes after meal, the ASX group had significantly lower blood glucose than the TX-SX group (71 ± 1 versus 77 ± 3 mg/dL; *P* = .05).

Neither fasting insulin levels (3.6 ± 0.8 versus 3.2 ± 0.9 *μ*U/mL; *P* = .7) nor insulin AUC (5478 ± 867 versus 4308 ± 801 *μ*U/mL/min; *P* = .5) during MMTT was different between the TX-SX and ASX groups. However, consistent with a hyperinsulinemic etiology of hypoglycemia, there was a trend towards greater insulin secretion in the TX-SX group including HOMA-IS (151 ± 41 versus 73 ± 20; *P* = .16) \[[@B24]\]. Insulin levels also tended to be higher in the TX-SX group at 30 and 60 minutes (time 30: 129 ± 27 versus 88 ± 20 *μ*U/mL, *P* = .30; time 60: 25 ± 5 versus 15 ± 4 *μ*U/mL, *P* = .15), though these did not reach statistical significance. Similarly, fasting C-peptide levels, C-peptide AUC, and repeated measures ANOVA for all time points during the MMTT were also not different between the TX-SX and ASX groups (data not shown). There was also no difference in insulin resistance between the TX-SX and ASX (HOMA-IR: 0.65 ± 0.13 versus ASX 0.45 ± 0.15; *P* = .16) \[[@B24]\].

We also assessed whether dumping syndrome physiology was contributing to symptoms during the MMTT \[[@B25]\]. However, we identified no difference in the average dumping scores of the two groups (65 ± 19 versus 60 ± 25, *P* = .8).

### 3.1.2. Continuous Glucose Monitoring {#sec3.1.2}

All subjects wore CGM for a minimum of 3 days. The TX-SX group tended to wear the device for longer and as a result had a higher number of average sensor values (interstitial glucose readings) (1099 ± 75 versus 721 ± 5; *P* = .01). As a result, all data for glycemic excursions are expressed as number of events of, or minutes spent in, hypo- or hyperglycemia *per day* (24-hour period of sensor recordings). Data are also expressed as percent time per day within a given glycemic range \[[@B26]\].

The average interstitial glucose was similar between the two groups (TX-SX: 104 ± 3 versus ASX 101 ± 3 mg/dL; *P* = 1.0). The TX-SX group had more total abnormal glucose excursions compared to the ASX group (8.5 ± 2.1 versus 3.8 ± 2.3; *P* = .05), that is, including both hypoglycemic (\<70 mg/dL) and hyperglycemic (\>180 mg/dL) glucose excursions.

HypoglycemiaCGM data were analyzed to determine frequency of hypoglycemia. Excursions during which interstitial glucose fell below 70 mg/dL per day occurred twofold more frequently in the symptomatic group, though this did not reach statistical significance (1.45 ± 0.42 versus 0.78 ± 0.44; *P* = .1). Similar patterns were observed when expressed as minutes per day or percent time per day spent in hypoglycemia (\<70 mg/dL), with hypoglycemia two times more frequent in the TX-SX group (TX-SX 63 ± 23 versus 34 ± 22 min per day, *P* = .28; 5.5 ± 1.9 versus 3.1 ± 2.0% time per day, *P* = .23). Excursions \<60 mg/dL were also not significantly different in the TX-SX and ASX groups (TX-SX 30 ± 14 versus 18 ± 12 min per day, *P* = .45; 2.6 ± 1.2 versus 3.1 ± 1.6% time per day, *P* = .39). The average minimum interstitial glucose values were not significantly lower in the TX-SX group (58 ± 5 versus 64 ± 7 mg/dL; *P* = .46).

HyperglycemiaThe maximum interstitial glucose value was significantly higher in the TX-SX group compared to the ASX group (213 ± 13 versus 167 ± 13 mg/dL; *P* = .03). Although the TX-SX group spent more minutes per day and more percent time per day in hyperglycemia (\>180 mg/dL), the difference was not statistically significant (TX-SX 11 ± 3 versus 9 ± 6 min per day, *P* = .59; 1.0 ± 0.3 versus 0.6 ± 0.4% time per day, *P* = .30).

### 3.1.3. Sensitivity and Specificity of Tests {#sec3.1.3}

Nine of 10 (90%) subjects who had experienced documented neuroglycopenia and were actively treated for post-bypass hypoglycemia syndrome developed hypoglycemia on CGM whereas only 3 of 9 (33%) demonstrated hypoglycemia on MMTT. In comparison, 3 of 6 asymptomatic subjects (50%) had hypoglycemia (\<70 mg/dL) on CGM, and even more, 3 of 5 (60%), on MMTT. This corresponds to a sensitivity of 90% and specificity of 50% for CGM, and 33% and 40% for MMTT ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

In this study, continuous glucose monitoring technology is compared to standardized mixed meal tolerance testing in a cohort of patients with a history of postgastric bypass neuroglycopenia and an asymptomatic postgastric bypass group. Patients with history of neuroglycopenia were referred for medical evaluation after initiation of therapeutic interventions. Our data suggest that CGM may be a better tool for the diagnosis of glycemic variability in patients with clinically significant post-bypass hypoglycemia than MMTT, even in treated patients. The diagnosis of post-gastric bypass hypoglycemia can be challenging to make, as hypoglycemic symptoms are nonspecific and can be difficult to distinguish from dumping syndrome \[[@B23]\]. There are currently no published recommendations to guide clinicians in the evaluation of patients suspected of having this syndrome. In our study, CGM had a sensitivity of 90% and specificity of 50%, compared to only 33% and 40% for MMTT, to distinguish patients with history of neuroglycopenia. The difference between testings may be because MMTT captures only one meal compared to many with CGM. Furthermore, the meal size, nutrient composition, and concurrent activity level, which are likely different in real life compared to research conditions, could play a role in the magnitude of postprandial hypoglycemia. Similarly, differences in counterregulatory or stress hormones, such as cortisol or catecholamines, could also attenuate postprandial hypoglycemia in the research setting. Until the reason for the difference in testing results can be better elucidated or additional diagnostic options are available, CGM appears to be a potentially valuable diagnostic test.

Measurement of interstitial glucose by CGM has previously been validated for the detection of hypoglycemia in other patient populations \[[@B27]\] and comparison of CGM to corresponding blood glucose levels demonstrated high accuracy during both euglycemia and hypoglycemia \[[@B26], [@B28]\]. A prior case report \[[@B23]\] found CGM useful to document hypoglycemia and response to treatment in a single post-bypass patient with type 2 diabetes. Vidal et al. \[[@B15]\] also used CGM in post-bypass patients, but subjects with symptomatic hypoglycemic episodes were specifically excluded. Our data therefore extend the current literature on glycemic excursions in response to gastric bypass, in particular in those who develop the rare but well-established syndrome of post-bypass neuroglycemia, which can result in life-threatening adverse events.

The data presented in this paper also provide additional insight into the effects of gastric bypass on glucose homeostasis. Patients who have had neuroglycopenia after gastric bypass experience an average of about 63 minutes per day with an interstitial glucose below 70 mg/dL and 30 minutes per day with an interstitial glucose below 60 mg/dL. Although interstitial glucose in the hypoglycemic range was increased about twofold in the TX-SX group, these findings were not statistically significant. This may be related to the fact that most subjects had such severe hypoglycemic episodes that treatment had already been initiated at the time of study and could not safely be withheld during CGM. It may have also been a result of small sample size, and alternatively, or perhaps additionally, statistical significance may not have been achieved because of the unexpectedly high rates of hypoglycemia detected on CGM in the asymptomatic group.

Indeed, even in those without symptoms of hypoglycemia after RYGB, low glucose levels may occur more frequently than commonly recognized. In our series, 3 out of 6 (50%) completely asymptomatic individuals had an interstitial glucose below 70 mg/dL; 2 out of 6 (33%) had a value below 60 mg/dL (and as low as 40 mg/dL). This is consistent with our prior report that one-third of asymptomatic patients developed hypoglycemia (plasma glucose \<60 mg/dL) after MMTT, but higher than the 12.5% of asymptomatic patients reported to have had hypoglycemia (glucose \<50 mg/dl) on CGM by Vidal et al. \[[@B15]\]. The differences may be related to different threshold definitions of hypoglycemia, small sample sizes in all studies, and methodology used for evaluation. Given that a disproportionate increase in death rates due to accidents has been reported after gastric bypass \[[@B7]\], finding significant rates of hypoglycemia in symptom-free post-bypass subjects raises the question about whether such accidents might be related to unrecognized hypoglycemia. Furthermore, why at similar glucose concentration some patients experience symptoms while others do not is not understood; adaptive mechanisms to hypoglycemia or susceptibility to neuroglycopenia may vary between individuals after gastric bypass, but these potential differences merit further study.

Our CGM data also show that patients with prior neuroglycopenia following gastric bypass demonstrate higher glycemic peaks when compared with asymptomatic post-bypass persons (maximum interstitial glucose value 212 versus 167 mg/dL; *P* = .03). Although we cannot directly address the causal factors potentially responsible for this pattern, this could be consistent with a rapid increase in plasma glucose after oral intake potentially leading to a high insulin peak and consequent hypoglycemia, as has previously been proposed \[[@B29]\]. However, our MMTT results did not support this, as post-MMTT glycemic response was not higher in the TX-SX than the ASX group, and prior published data addressing this question have not been consistent \[[@B13], [@B29]\]. We previously reported that glucose levels during the 30 minutes after MMTT were lower in a group of subjects that had experienced neuroglycopenia (but were treatment naive) compared to post-RYGB asymptomatic controls \[[@B13]\]. In contrast, Kim et al. \[[@B29]\] found that 30-minute glucose values after a 75 g oral glucose tolerance test were higher in a symptomatic hypoglycemia compared to an asymptomatic post-bypass group. While differences in these findings may relate to differences in the type and carbohydrate content of the test stimulus, it is interesting that both studies did find that time-to-peak glucose was shorter in the symptomatic patients. More studies are clearly needed to better characterize postprandial glucose, insulin, and other metabolically important hormone dynamics in patients who develop significant hypoglycemia after bariatric surgery.

Our main study limitation is the small sample size. However, given that neuroglycopenia after gastric bypass is a relatively rare phenomenon, the size of the TX-SX cohort assembled for this study is substantial. Furthermore, previous medical management for neuroglycopenia could attenuate glycemic variability and affect conclusions.

5. Conclusions {#sec5}
==============

Asymptomatic hypoglycemia is more frequent than commonly recognized in post-bypass patients. The clinical importance of these events, and why at similar glucose levels some patients experience hypoglycemic symptoms while others do not remains incompletely understood. The underlying pathophysiology of the post-bypass hypoglycemia syndrome, including post-prandial glucose and hormonal dynamics, needs to be better characterized and warrants continued investigation. For clinicians evaluating patients for the rare but potentially life-threatening complication of neuroglycopenia after gastric bypass surgery, CGM may be a valuable diagnostic test.
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###### 

Characteristics of study subjects.

  -----------------------------------------------------------------------------------------------------------------------------
                                            Gastric bypass with neuroglycopenia (TX-SX)\   Gastric bypass asymptomatic (ASX)\
                                            (*n* = 10)                                     (*n* = 6)
  ----------------------------------------- ---------------------------------------------- ------------------------------------
  Age (years)                               51 ± 4                                         52 ± 5

  Preoperative body mass index (kg/m^2^)    50.1 ± 2.5                                     46.2 ± 3.4

  Body mass index at evaluation (kg/m^2^)   29.8 ± 1.9                                     30.0 ± 2.7

  Magnitude of weight loss (kg)             53.0 ± 8.8                                     45.0 ± 5.4

  Postoperative duration (years)            8.9 ± 2.4                                      5.3 ± 0.9

  Hemoglobin A1c (%)                        5.7 ± 0.1                                      5.7 ± 0.1

  Total cholesterol (mg/dL)                 170.1 ± 7.9                                    173.5 ± 8.4

  Triglycerides (mg/dL)                     66.2 ± 4.9                                     72.5 ± 5.5

  LDL cholesterol (mg/dL)                   98.9 ± 7.2                                     93.0 ± 10.1

  HDL cholesterol (mg/dL)                   62.2 ± 4.3                                     73.8 ± 8.8

  Systolic blood pressure (mm Hg)           118.1 ± 4.7                                    117.5 ± 6.9

  Diastolic blood pressure (mm Hg)          67.1 ± 2.1                                     66.5 ± 2.9

  Dumping score                             64.7 ± 18.7                                    60.5 ± 25.5
  -----------------------------------------------------------------------------------------------------------------------------

Characteristics presented as mean ± standard error. There was no statistically significant difference in these variables between the two groups.

###### 

Results from continuous glucose monitoring and mixed meal tolerance testing on post-gastric bypass subjects with documented episodes of neuroglycopenia on medical treatment (TX-SX) or without any symptoms of hypoglycemia (ASX).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                Gastric bypass with neuroglycopenia\   Gastric bypass asymptomatic\   *P* value
                                                                                                (TX-SX)                                (ASX)                          
  --------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------ ------------
  *CGM*                                                                                                                                                               

  Average interstitial glucose (mg/dL)                                                          104 ± 3                                101 ± 3                        *P* = 1.00

  Average number of daily excursions \<70 mg/dL                                                 1.45 ± 0.42                            0.78 ± 0.44                    *P* = .10

  Minutes/day glucose \<70 mg/dL                                                                63 ± 23                                34 ± 22                        *P* = .28

  Minutes/day glucose \<60 mg/dL                                                                30 ± 14                                18 ± 12                        *P* = .45

  Average minimum glucose (mg/dL)                                                               58 ± 5                                 64 ± 7                         *P* = .46

  Average maximum glucose (mg/dL)                                                               213 ± 13                               167 ± 13                       *P* = .03

  Minutes/day glucose \>180 mg/dL                                                               11 ± 3                                 9 ± 6                          *P* = .59

  Total abnormal glucose excursions (hypoglycemic \<70 mg/dL, plus hyperglycemic \>180 mg/dL)   8.5 ± 2.1                              3.8 ± 2.3                      *P* = .05

                                                                                                                                                                      

  *MMTT*                                                                                                                                                              

  Fasting blood glucose (mg/dL)                                                                 73 ± 1                                 75 ± 2                         *P* = .40

  Glucose area under curve (0--120 mins) (mg/dL/min)                                            3399 ± 695                             2285 ± 782                     *P* = .50

  Glucose at time 120 mins (mg/dL)                                                              71 ± 1                                 77 ± 3                         *P* = .05

  Fasting insulin (*μ*U/mL)                                                                     3.6 ± 0.8                              3.2 ± 0.9                      *P* = .70

  Insulin at time 30 mins (*μ*U/mL)                                                             129 ± 27                               88 ± 20                        *P* = .30

  Insulin at time 60 mins (*μ*U/mL)                                                             25 ± 5                                 15 ± 4                         *P* = .15

                                                                                                                                                                      

  *Sensitivity\**                                                                                                                                                     

  CGM                                                                                           9/10 (90%)                                                            

  MMTT                                                                                          3/9 (33%)                                                             

                                                                                                                                                                      

  *Specificity\*\**                                                                                                                                                   

  CGM                                                                                           3/6 (50%)                                                             

  MMTT                                                                                          2/5 (40%)                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data presented as mean ± standard error. CGM: continuous glucose monitoring; MMTT: mixed meal tolerance testing.

*\**Sensitivity = number of true positives/(number of true positives + number of false negatives).

*\*\**Specificity = number of true negatives/(number of true negatives + number of false positives). True positive is defined as a numerical value of hypoglycemia (glucose \<70 mg/dL) during a test in a subject with the prior clinical occurrence of neuroglycopenia (TX-SX group). A false positive is defined as a numerical value of hypoglycemia during a test in a subject without the presence or history of symptoms.
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